FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

Pin It

This story appears to have been written by the PR department of the company that makes Invega- the first once-monthly atypicle antipsychotic approved for Schizophrenia in the United States.

Link to full article

Submitted by: Darrell H.

Speak Your Mind